SCHEDULE 13D/A: Major Shareholder Charles Cherington Boosts Stake in Ernexa Therapeutics to 37.9% Following Private Placement and Dividend

Charles Cherington has significantly increased his beneficial ownership in Ernexa Therapeutics Inc. to 37.9% of outstanding common stock through participation in a private placement and a dividend payment.

Summary

• Charles Cherington, the reporting person, now beneficially owns 41,690,775 shares of Ernexa Therapeutics Inc. common stock.
• This represents 37.9% of the Issuer's total outstanding common stock, calculated based on an aggregate of 110,128,860 shares.
• The increase in ownership is primarily due to the acquisition of 21,241,163 shares in the "Second Closing" of a private placement.
• An additional 16,978 shares were received as a payment-in-kind semi-annual dividend on 71,306 shares of Series A Preferred Stock held by the Reporting Person, paid on June 2, 2025.
• The private placement, initiated under a Purchase Agreement dated April 2, 2025, involved the Issuer agreeing to sell 69,311,654 shares (or pre-funded warrants) at a purchase price of $0.1046 per share.
• The private placement was conducted in two separate closings to comply with Nasdaq Listing Rules 5635(b) and 5635(d), with the Second Closing occurring on June 9, 2025, after stockholder approval was obtained on June 2, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a significant shareholder's increased confidence through further investment and the successful completion of a capital raise, which are positive. However, the substantial dilution from the capital raise and dividend payment in shares could be viewed negatively by non-participating shareholders.

Positives

• A significant shareholder, Charles Cherington, has increased his stake, indicating continued confidence in Ernexa Therapeutics Inc. and its future prospects.
• The company successfully completed the Second Closing of a private placement, raising capital by issuing 47,717,087 common shares and pre-funded warrants to purchase up to 9,332,000 shares.
• The private placement was priced at $0.1046 per share, providing a clear valuation for the capital raise and demonstrating investor interest at that price point.

Negatives

• The issuance of a large number of new shares (47,717,087 common shares plus warrants for 9,332,000 shares) in the Second Closing, along with the dividend paid in shares, indicates significant dilution for existing shareholders not participating in the private placement.
• The necessity for a private placement suggests the company required additional capital, which could imply ongoing funding needs or operational challenges that necessitate external financing.

Risks

• Dilution Risk: The issuance of a substantial number of new common shares and pre-funded warrants in the private placement, along with the payment of dividends in common stock, significantly dilutes the ownership percentage of existing shareholders who did not participate.
• Regulatory Compliance Risk: The private placement was structured in two closings to comply with Nasdaq Listing Rules 5635(b) and 5635(d), indicating potential complexities in capital raising activities and the need for specific regulatory adherence.

Future Outlook

The reporting person has stated that he has no present plan or proposal that relates to, or could result in, any events typically associated with changes in control or significant corporate transactions, such as mergers, liquidations, or major business changes.

Industry Context

This filing, a Schedule 13D amendment, primarily details a change in beneficial ownership by a significant shareholder following a private placement. It does not provide sufficient information to analyze broader industry trends or competitive positioning of Ernexa Therapeutics Inc. beyond the fact that it is raising capital through equity issuance.

Stakeholder Impact

• Shareholders: Existing shareholders who did not participate in the private placement experienced significant dilution due to the issuance of new common stock and pre-funded warrants, as well as the payment of dividends in shares.
• Company (Ernexa Therapeutics Inc.): The company successfully raised capital through the private placement, which provides funding for its operations and strategic initiatives.

Key Dates

Keywords

Ernexa Therapeutics Inc., Charles Cherington, Schedule 13D, Beneficial Ownership, Private Placement, Common Stock, Series A Preferred Stock, Share Dilution, SEC Filing, Capital Raise, Nasdaq Listing Rules